IceCure Medical to Report 2024 Full Year Financial & Operational Results on March 27, 2025
IceCure Medical (Nasdaq: ICCM), a developer of minimally-invasive cryoablation technology for tumor treatment, has scheduled its 2024 full year financial and operational results announcement for March 27, 2025. The company will release its results before the Nasdaq market opens, followed by a conference call at 10:00 AM EDT.
The conference call will be accessible via US dial-in (1-888-407-2553) and International dial-in (+972-3-918-0696). A live webcast will be available, with a recording subsequently posted on the company's investor relations website.
IceCure Medical (Nasdaq: ICCM), sviluppatore di tecnologia di criobrazione minimamente invasiva per il trattamento dei tumori, ha programmato l'annuncio dei risultati finanziari e operativi per l'intero anno 2024 per il 27 marzo 2025. L'azienda pubblicherà i risultati prima dell'apertura del mercato Nasdaq, seguiti da una conferenza telefonica alle 10:00 EDT.
La conferenza telefonica sarà accessibile tramite numero di telefono statunitense (1-888-407-2553) e numero internazionale (+972-3-918-0696). Sarà disponibile anche una diretta streaming, con una registrazione successivamente pubblicata sul sito web delle relazioni con gli investitori dell'azienda.
IceCure Medical (Nasdaq: ICCM), un desarrollador de tecnología de crioblasia mínimamente invasiva para el tratamiento de tumores, ha programado el anuncio de sus resultados financieros y operativos del año completo 2024 para el 27 de marzo de 2025. La compañía publicará sus resultados antes de la apertura del mercado Nasdaq, seguido de una conferencia telefónica a las 10:00 AM EDT.
La conferencia telefónica será accesible a través del número de EE. UU. (1-888-407-2553) y el número internacional (+972-3-918-0696). También estará disponible una transmisión en vivo, con una grabación que se publicará posteriormente en el sitio web de relaciones con inversores de la empresa.
IceCure Medical (Nasdaq: ICCM), 종양 치료를 위한 최소 침습적 냉동 절제 기술 개발업체가 2024년 전체 연도 재무 및 운영 결과 발표를 2025년 3월 27일로 예정했습니다. 회사는 나스닥 시장 개장 전에 결과를 발표하고, EDT 기준 오전 10시에 컨퍼런스 콜을 진행할 예정입니다.
컨퍼런스 콜은 미국 전화번호 (1-888-407-2553)와 국제 전화번호 (+972-3-918-0696)를 통해 접근할 수 있습니다. 라이브 웹캐스트가 제공되며, 이후 회사의 투자자 관계 웹사이트에 녹음이 게시될 예정입니다.
IceCure Medical (Nasdaq: ICCM), un développeur de technologie de cryoablation peu invasive pour le traitement des tumeurs, a programmé l'annonce de ses résultats financiers et opérationnels pour l'année complète 2024 pour le 27 mars 2025. L'entreprise publiera ses résultats avant l'ouverture du marché Nasdaq, suivie d'une conférence téléphonique à 10h00 EDT.
La conférence téléphonique sera accessible via le numéro américain (1-888-407-2553) et le numéro international (+972-3-918-0696). Un webinaire en direct sera disponible, avec un enregistrement qui sera ensuite publié sur le site web des relations avec les investisseurs de l'entreprise.
IceCure Medical (Nasdaq: ICCM), ein Entwickler von minimal-invasiver Kryoablationstechnologie zur Tumorbehandlung, hat die Bekanntgabe seiner finanziellen und operativen Ergebnisse für das gesamte Jahr 2024 auf den 27. März 2025 terminiert. Das Unternehmen wird seine Ergebnisse vor der Eröffnung des Nasdaq-Marktes veröffentlichen, gefolgt von einer Telefonkonferenz um 10:00 Uhr EDT.
Die Telefonkonferenz wird über die US-Telefonnummer (1-888-407-2553) und die internationale Telefonnummer (+972-3-918-0696) zugänglich sein. Ein Live-Webcast wird verfügbar sein, mit einer anschließenden Aufzeichnung, die auf der Investor-Relations-Website des Unternehmens veröffentlicht wird.
- None.
- None.
Conference call & webcast info:
Thursday, March 27, 2025, at 10:00 am EDT
US: 1-888-407-2553
A live webcast will be available at: https://Veidan.activetrail.biz/IcecureQ4-2024.
A recording of the webcast will be available at: ir.icecure-medical.com/.
About IceCure Medical
IceCure Medical (Nasdaq: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective alternative to hospital surgical tumor removal that is easily performed in a relatively short procedure. The Company's flagship ProSense® system is marketed and sold worldwide for the indications cleared and approved to date including in the
IR Contact:
Email: investors@icecure-medical.com
Michael Polyviou
Phone: 732-232-6914
Todd Kehrli
Phone: 310-625-4462
Logo - https://mma.prnewswire.com/media/2319310/4496307/IceCure_Medical_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/icecure-medical-to-report-2024-full-year-financial--operational-results-on-march-27-2025-302407150.html
SOURCE IceCure Medical
FAQ
When will IceCure Medical (ICCM) release its 2024 full year financial results?
How can investors join IceCure Medical's (ICCM) Q4 2024 earnings call?
Where can I find the replay of IceCure Medical's (ICCM) 2024 earnings webcast?
What time is IceCure Medical's (ICCM) Q4 2024 earnings conference call?
